Application of apparent modified nucleoside in tumor treatment
By using apparently modified nucleosides such as 5-aldehyde cytidine, it uses its interaction with acute myeloid leukemia cells with high CDA expression to produce toxic deamination products, insert DNA strands, resulting in cell DNA damage and proliferation Inhibition solves the problem of cytarabine deamide failure and achieves the specific killing and treatment effect of acute myeloid leukemia cells.
Patent Information
- Application Number
- CN202410764237.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-14
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-06-14
AI Technical Summary
The existing cytarabine has deamination failure problem in the treatment of acute myeloid leukemia, resulting in limited treatment effect and off-target toxicity to normal tissues, making it difficult to achieve specific killing of tumor cells.
Using apparently modified nucleosides such as 5-aldehyde cytidine, 5-hydroxymethylcytidine and 5-hydroxymethyluridine, the toxic deamination products are produced by interacting with acute myeloid leukemia cells with high expression of CDA. , insert DNA strands, resulting in cellular DNA damage and proliferation inhibition, achieving targeted therapy.
It effectively inhibits the proliferation of acute myeloid leukemia cells with high expression of CDA, significantly reduces the toxic side effects on normal cells, achieves specific killing of tumor cells, and improves the therapeutic effect.
Smart Images

Figure CN119015298A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to the application of epigenetically modified nucleosides in treating tumors. Background Art
[0002] Acute myeloid leukemia is a type of blood tumor with a high incidence rate and is difficult to cure. At present, the clinical treatment of this disease is mainly chemotherapy, which mainly uses nucleoside analogs and base analogs to inhibit tumor cell proliferation to achieve therapeutic effects. Among them, cytarabine (Ara-C) is the most commonly used nucleoside analog. It mainly acts on the S phase of cell division, inhibiting the synthesis of cell DNA and interfering with cell proliferation. As a classic chemotherapy drug for acute myeloid leukemia, Ara-C is phosphorylated to form Ara-CTP under the action of phosphokinase after entering the tumor cell, competing with endogenous dCTP (2'-deoxycytidine5'-triphosphate, deoxycytidine triphosphate) for DNA polymerase to be incorporated into the DNA chain, blocking DNA synthesis, thereby inhibiting cell proliferation. The rapid proliferation characteristics of tumor cells accompanied by frequent DNA synthesis in cells provide opportunities for Ara-C to exert a good therapeutic effect. However, the proliferation of normal tissue cells in the body also requires DNA replication, which means that Ara-C will cause off-target toxicity to normal tissues and organs.
[0003] In addition, although cytarabine has achieved certain therapeutic effects in chemotherapy for leukemia, there is a challenge of deamination failure of cytarabine during the treatment process. It is reported that Ara-C entering the cell will be recognized by the intracellular deaminase CDA (Cytidine deaminase) and deaminated into the non-cytotoxic deamination product Ara-U (uracil arabinoside), and CDA is often highly expressed in acute myeloid leukemia cells, which limits the clinical application of Ara-C and increases the difficulty of treating acute myeloid leukemia. Therefore, it is crucial to find nucleoside analogs that are specific to tumor cells and can avoid failure due to deamination reactions for the treatment of acute myeloid leukemia. Summary of the invention
[0004] The purpose of the present invention is to provide the application of epigenetically modified nucleosides in the treatment of tumors, lay a foundation for the targeted treatment of acute myeloid leukemia with high CDA expression, and expand the application potential of epigenetically modified nucleosides in the treatment of leukemia.
[0005] The present invention provides an application of an apparent modified nucleoside in preparing a drug for treating tumors. The apparent modified nucleoside comprises at least one of the following: 5-aldehyde cytidine, 5-hydroxymethyl cytidine and 5-hydroxymethyl uridine.
[0006] Preferably, the tumor comprises a blood cancer.
[0007] Preferably, the tumor treatment includes inhibiting the proliferation of cancer cells.
[0008] Preferably, the cancer cells include acute myeloid leukemia cells.
[0009] Preferably, the acute myeloid leukemia cells include HL-60 cells and / or THP-1 cells.
[0010] The present invention also provides a tumor cell proliferation inhibitor, comprising at least one of the following: 5-aldehyde cytidine, 5-hydroxymethyl cytidine and 5-hydroxymethyl uridine;
[0011] Among them, 5-formylcytidine, 5-hydroxymethylcytidine, and 5-hydroxymethyluridine all inhibited the proliferation of HL-60 cells;
[0012] 5-Hydroxymethyluridine has an inhibitory effect on the proliferation of THP-1 cells.
[0013] The present invention also provides a targeted drug for inhibiting acute myeloid leukemia cells with high CDA expression, wherein the active ingredient includes 5-formyl cytidine.
[0014] Preferably, the method comprises treating acute myeloid leukemia cells with high CDA expression with 5-aldehyde cytidine.
[0015] Preferably, during the treatment, the concentration of 5-formylcytidine is not less than 10 μM and the treatment time is not less than 48 hours.
[0016] Preferably, the acute myeloid leukemia cells with high CDA expression include HL-60 cells.
[0017] Beneficial effects: The present invention co-cultures different concentrations of 5-formylcytidine (5fdC), 5-hydroxymethylcytidine (5hmdC), 5-hydroxymethyluridine (5hmdU), 5-carbonylcytidine (5cadC) and 5-methylcytidine (5md) with acute myeloid leukemia cells HL-60 and THP-1 for 144 hours, and counts and subcultures every 48 hours to examine the proliferation of cells, thereby screening the epigenetic modified nucleosides that have a proliferation inhibitory effect on acute myeloid leukemia cells. The results show that after HL-60 cells are treated with 5fdC, their proliferation is significantly and continuously inhibited. In addition, as the treatment time increases, 5hmdC and 5hmdU gradually show proliferation inhibition on the proliferation of HL-60 cells. Only 5hmdU shows an inhibitory effect on the proliferation of THP-1 cells, while 5fdC and 5hmdC do not show a significant inhibitory effect. The results showed that epigenetic modified nucleosides had an inhibitory effect on the proliferation of different acute myeloid leukemia cells, among which 5fdC was the most toxic to HL-60 cells, while THP-1 cells were most sensitive to 5hmdU.
[0018] The present invention uses the apparent modified nucleoside 5fdC as a proliferation inhibitor of acute myeloid leukemia cells with high CDA expression, and directly treats the cells to achieve a tumor killing effect. Compared with non-tumor cells, CDA highly expressed in acute myeloid leukemia tumor cells can effectively convert the apparent modified nucleoside 5fdC into toxic 5fdU, thereby achieving the specific killing effect of the apparent modified nucleoside on the tumor cells of acute myeloid leukemia and realizing targeted treatment. In addition, the rapid proliferation of tumor cells can more effectively incorporate the deamination product of the apparent modified nucleoside 5fdC into the genome through DNA replication, triggering cell DNA damage, and a large amount of DNA damage can cause cell proliferation inhibition and ultimately lead to tumor cell death; at the same time, the apparent modified nucleoside has only slight toxic side effects on normal cells, but the toxic side effects are much smaller than those of tumor cells, indicating that the apparent modified nucleoside has a specific killing ability on acute myeloid leukemia cells with high CDA expression. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 The results of the proliferation inhibition analysis of HL-60 (A) and THP-1 (B) cells by epitope-modified nucleosides are shown in Figure 2;
[0020] Figure 2 The results of the correlation analysis between the inhibitory effect of 5fdC on cell proliferation and the expression of cytidine deaminase (CDA); Figure A: Analysis of the cytotoxic effect of β-ME in the cell culture medium on 5fdC; B: qPCR detection of CDA expression in HL-60 and THP-1 cells; C: Analysis of the inhibitory effect of 5fdC combined with THU on HL-60 cell proliferation; D: Analysis of the inhibitory effect of 5fdC on THP-1 (CDAOE) cells;
[0021] Figure 3 Validation of CDA overexpression amplification plasmid and construction verification of THP-1 (CDAOE) cells; A: pLVX-EF1a-hCDA (NM_001785) -EGFP-IRES-Puro plasmid map; B: gel electrophoresis verification of enzyme digestion products; C: plasmid sequencing comparison; D: fluorescence imaging of THP-1 cells infected with CDA overexpressing lentivirus (100×); E: products of THP-1 and its overexpression cell lines (lane 1: CDA product in THP-1; lanes 2, 3: CDA product in THP-1-NC; lanes 4, 5: CDA product in THP-1 (CDA OE); lane 6: CDA primer control; lane 7: β-actin product in THP-1; lanes 8, 9: β-actin product in THP-1-NC; lanes 10, 11: THP-1 (CDA Lane OE) β-actin product; Lane 12: β-actin primer control)
[0022] Figure 4 Figure 2 is the result of apoptosis analysis of HL-60 and THP-1 cells after treatment with 5fdC;
[0023] Figure 5 The results of the analysis of DNA damage in HL-60 and THP-1 cells after treatment with apparent modified nucleosides are shown in Figures A and B, respectively, are protein print analysis and relative content statistical bar graphs of γ-H2AX protein in HL-60 cells after treatment with apparent modified nucleosides; C and D, respectively, are protein print analysis and relative content statistical bar graphs of γ-H2AX protein in THP-1 cells after treatment with apparent modified nucleosides; E and F, respectively, are comet assay characterization of DNA damage in HL-60 cells after treatment with apparent modified nucleosides and comet tail length statistical graphs; G and H, respectively, are comet assay characterization of DNA damage in THP-1 cells after treatment with apparent modified nucleosides and comet tail length statistical graphs;
[0024] Figure 6 The results of damage recovery analysis after epigenetic modification nucleosides inhibited acute myeloid leukemia cells; Figure A: 5fdC damage recovery analysis of HL-60 cells and THP-1 cells; B: 5hmC damage recovery analysis of HL-60 cells and THP-1 cells;
[0025] Figure 7The results of the specific analysis of the inhibition of acute myeloid leukemia cell proliferation by epigenetic modified nucleosides are shown in Figure A; Figure A: flow cytometry analysis of the effect of epigenetic modified nucleosides on the apoptosis of HEK293 cells; B and C are the protein imprint characterization and relative content analysis of γ-H2AX protein in HEK293 cells after treatment with epigenetic modified nucleosides; D and E are the comet assay characterization of DNA damage in HEK293 cells after treatment with epigenetic modified nucleosides and the statistical bar graph of comet tail length. DETAILED DESCRIPTION
[0026] The present invention provides an application of an apparent modified nucleoside in preparing a drug for treating tumors, wherein the apparent modified nucleoside comprises at least one of the following: 5-formaldehyde cytidine (5fdC), 5-hydroxymethyl cytidine (5hmdC) and 5-hydroxymethyl uridine (5hmdU).
[0027] The tumor of the present invention preferably includes blood cancer, more preferably includes leukemia, and most preferably includes acute myeloid leukemia. In the embodiment, HL-60 cells (human promyelocytic cell line) and THP-1 cells (human leukemia monocytic cell line) are used as examples for illustration, but they cannot be identified as the entire protection scope of the present invention. The treatment of tumors of the present invention preferably includes inhibiting cancer cell proliferation and ultimately inducing cancer cell apoptosis.
[0028] In the example of the present invention, 5fdC, 5hmdC, 5hmdU, 5cadC and 5md purchased from Jena Bioscience were prepared into solutions of different concentrations and co-cultured with acute myeloid leukemia cells HL-60 and THP-1, respectively. The results showed that after HL-60 cells were treated with 5fdC, their proliferation was significantly and continuously inhibited; and as the treatment time increased, 5hmdC and 5hmdU gradually showed proliferation inhibition on the proliferation of HL-60 cells; and only 5hmdU showed an inhibitory effect on the proliferation of THP-1 cells, indicating that the epitope-modified nucleosides have an inhibitory effect on the proliferation of different acute myeloid leukemia cells, among which 5fdC is the most toxic to HL-60 cells, while THP-1 cells are most sensitive to 5hmdU.
[0029] The present invention also provides a tumor cell proliferation inhibitor, comprising at least one of the following: 5-aldehyde cytidine, 5-hydroxymethyl cytidine and 5-hydroxymethyl uridine;
[0030] Among them, 5-formylcytidine, 5-hydroxymethylcytidine, and 5-hydroxymethyluridine all inhibited the proliferation of HL-60 cells;
[0031] 5-Hydroxymethyluridine has an inhibitory effect on the proliferation of THP-1 cells.
[0032] The present invention also provides a targeted drug for inhibiting acute myeloid leukemia cells with high CDA expression, wherein the active ingredient comprises epigenetically modified 5-formyl cytidine.
[0033] In the examples of the present invention, it was found that the presence of the reducing agent β-mercaptoethanol (2-Mercaptoethano, β-ME) did not affect the inhibitory effect of 5fdC on the proliferation of HL-60 cells; the high sensitivity of HL-60 cells to the 5fdC epitope-modified nucleoside is likely driven by the highly expressed CDA in the cells, that is, after 5fdC is deaminated by CDA in the cells, the cytotoxic uridine derivatives 5hmdU and 5fdU are produced. After 5hmdU and 5fdU are inserted into genomic DNA, they will cause extensive DNA damage, thereby inducing cell cycle arrest and Cell death; then the CDA inhibitor Tetrahydrouridine (THU) was used to inhibit the activity of CDA highly expressed in HL-60 cells. It was found that THU significantly weakened the inhibitory effect of 5fdC on the proliferation of HL-60 cells after inhibiting the activity of CDA, indicating that the cytotoxic effect of 5fdC may depend on the highly expressed CDA in acute myeloid leukemia cells; and the epigenetic modification of nucleosides inhibits cell proliferation by triggering cell apoptosis, that is, epigenetic modification of nucleosides can cause DNA breakage in acute myeloid leukemia cells, leading to cell apoptosis. The DNA damage of epigenetic modification of nucleosides to leukemia cells depends on the expression of CDA in the cells, which lays the foundation for the targeted therapy of non-classical epigenetic modification of nucleosides.
[0034] In the examples of the present invention, the targeted toxicity of the epigenetic modification of 5fdC on acute myeloid leukemia cells with high CDA expression was also investigated. The results showed that the effect of the epigenetic modification nucleoside on the apoptosis of HEK293 cells was almost negligible, which means that 5fdC only caused slight damage to normal cells and had no obvious toxicity, indicating that the epigenetic modification nucleoside had only slight toxic side effects on normal cells, but the toxic side effects were much smaller than those on tumor cells, suggesting that the epigenetic modification nucleoside was specific in killing acute myeloid leukemia cells with high CDA expression.
[0035] The present invention preferably uses 5-formylcytidine to treat acute myeloid leukemia cells with high CDA expression, and during the treatment, the concentration of 5-formylcytidine is preferably not less than 10 μM and the time is not less than 48 hours. The acute myeloid leukemia cells with high CDA expression in the present invention preferably include HL-60 cells.
[0036] In order to further illustrate the present invention, the application of the apparent modified nucleosides provided by the present invention in treating tumors is described in detail below in conjunction with the examples, but they should not be construed as limiting the scope of protection of the present invention.
[0037] The test materials used in the examples of the present invention are commercial test materials obtained through conventional commercial channels in the art, such as HL-60 (human promyelocytic cell line), THP-1 (human leukemia monocytic cell line) and HEK293 (Human embryonic kidney cell line), which are all purchased from ATCC and cultured in an incubator with a cell culture environment of 37°C and 5% CO2. The complete culture medium of HL-60 is composed of a complete culture medium containing 20% FBS and 1% double antibody, i.e., IMDM+20% FBS+1% double antibody, and the complete culture medium of THP-1 and HEK293 cells is composed of a complete culture medium of RPMI 1640 containing 10% FBS and 1% double antibody. It is worth noting that the culture of THP-1 also requires the addition of 5 μM β-mercaptoethanol (2-Mercaptoethano, β-ME) to the culture medium, namely RPMI 1640+10% FBS+1% double antibody+5 μM β-mercaptoethanol, and the centrifugation conditions are 1000 rpm, 3 min.
[0038] The methods used in the embodiments of the present invention are all conventional methods in the art, such as:
[0039] (1) Proliferation experiment: 8.0×10 5 Cells were seeded in six-well plates, and epigenetic modified nucleosides with final concentrations of 10μM 5fdC, 100μM 5hmdC, 50μM 5hmdU, 100μM 5mdC, and 100μM 5cadC and 1‰ DMSO were added to the cells for co-incubation. The cells were counted and subcultured every 48h, and the culture medium in the six-well plate was collected, centrifuged at 1000rpm for 3min, the supernatant was discarded with a pipette, and 1mL of fresh culture medium was added to resuspend the cells. 10μL of the cell suspension was diluted 10 times and counted under a microscope. The cells were cultured for a total of 144h to draw the proliferation curve.
[0040] (2) Western Blot: Cell treatment was the same as the proliferation experiment. RIPA lysis buffer (Solabo) was used to extract total protein from cells treated with epitope-modified nucleosides and denatured at 100°C. TGX Stain-Free TMFASTCASTTM Acrylamide Kit was used to prepare 5-15% SDS-PAGE gel for electrophoresis of each group of proteins. After exposure and observation of the total protein in each lane, the membrane was transferred to a nitrocellulose membrane (NC membrane), blocked with 5% skim milk powder at room temperature for 1 hour, and incubated overnight with γ-H2AX primary antibody purchased from Cell Signaling Technology at 1:2000, washed 3 times with PBST, 10 minutes each time. Incubated with 1:5000 horseradish peroxidase (HRP)-labeled goat anti-rabbit secondary antibody (Hua'an Biotechnology) at room temperature for 1 hour, washed 3 times with PBST, 10 minutes each time. ECL chemiluminescent solution was used for development.
[0041] (3) Comet assay: After the cells were incubated with 10 μM 5fdC, 100 μM 5hmdC, 50 μM 5hmdU, 100 μM 5mdC, and 100 μM 5cadC for 144 h, the cells were collected and lysed with a lysis buffer (100 mM Na2EDTA, 1.2 M NaCl, 0.26 M NaOH, 0.1% sodium lauroyl amine, pH adjusted to >13, and stored at 4°C) for later use. H2O2 is a strong oxidant, and the reactive oxygen species (ROS) produced can directly act on DNA, causing damage to cellular DNA. Therefore, cells treated with 0.001% H2O2 for 20 min were selected as the positive control group of the experiment. Subsequently, 100 μL of the dissolved 0.8% normal melting point agarose was taken and added to the rough surface of the slide, and the gel was evenly spread and solidified at 4°C for 10 min as the first layer of gel. Then, 300 μL of cell lysate was mixed with 900 μL of 0.75% low melting point agarose at room temperature, 100 μL was added to the first layer of gel, and a cover glass was added, and solidified at 4°C for 5 min. After solidification, the slides were washed and characterized by electrophoresis (voltage 20 V, current 25 mA, electrophoresis 20 min). Finally, the slides were washed with ultrapure water and placed in 30 mL of staining solution (3 μL 10000×SYBR Green + 30 mL ultrapure water) for staining at room temperature for 15 min, observed under a fluorescence microscope, and analyzed with Image J.
[0042] (4) TRIzol RNA extraction: Collect cells that have been treated with epitope-modified nucleosides for 144 h and wash them once with PBS. Add an appropriate amount of TRIzol to the cell pellet and let it stand at room temperature for 5 min to fully lyse the cells. Then add chloroform (200 μL chloroform for 1 mL TRIzol), shake vigorously for 15 s, let it stand at room temperature for 2-3 min, and then centrifuge at 4°C, 12000g for 15 min. After centrifugation, transfer the aqueous phase to a new EP tube, add isopropanol (500 μL isopropanol for 1 mL TRIzol), let it stand at room temperature for 10 min, and then centrifuge at 4°C, 12000g for 10 min. After centrifugation, take the supernatant, add 75% ethanol to mix (1 mL 75% ethanol is added to 1 mL TRIzol), centrifuge at 4°C, 7500g for 5 min, and wash twice in total. After washing, aspirate the supernatant as completely as possible, let the pellet stand at room temperature for 15 min, dry the RNA, and dissolve it in an appropriate volume of DEPC-treated water. After measuring the concentration, store at -80°C.
[0043] (5) Detection of cell apoptosis by flow cytometry: Collect cells that have been incubated with epigenetic modification nucleosides of 10 μM 5fdC, 100 μM 5hmdC, 50 μM 5hmdU, 100 μM 5mdC, and 100 μM 5cadC for 144 h, and wash the cells twice with PBS containing 0.1% BSA (the subsequent PBS is prepared) at 1000 rpm for 3 min, then add 500 μL of Binding Buffer and gently blow to form a single cell suspension, then add 5 μL of Annexin V-FITC and mix well, then add 5 μL of Propidium Iodide, mix well, and react at room temperature in the dark for 5 to 10 min. Finally, wash the cells with PBS and resuspend them into a cell suspension, filter with a 200-mesh filter, and detect on the flow cytometer.
[0044] Example 1
[0045] (1) Screening for epigenetic modified nucleosides that have proliferation inhibitory effects on acute myeloid leukemia cells
[0046] The present invention co-cultures acute myeloid leukemia cells HL-60 and THP-1 with different concentrations of 5-formylcytidine (5fdC), 5-hydroxymethylcytidine (5hmdC), 5-hydroxymethyluridine (5hmdU), 5-carbonylcytidine (5cadC) and 5-methylcytidine (5md) for 144 hours, and counts and passages the cells every 48 hours to examine the proliferation of the cells.
[0047] The results are as follows Figure 1As shown in A, the proliferation of HL-60 cells was significantly and continuously inhibited after being treated with 5fdC. As the treatment time increased, 5hmdC and 5hmdU gradually inhibited the proliferation of HL-60 cells. However, 5mdC and 5cadC did not have a significant effect on the proliferation of HL-60 cells.
[0048] The results are as follows: Figure 1 As shown in B, only 5hmdU showed an inhibitory effect on THP-1 cell proliferation, while 5fdC and 5hmdC did not show obvious inhibitory effect.
[0049] Depend on Figure 1 It can be seen that the epitope-modified nucleosides have an inhibitory effect on the proliferation of different acute myeloid leukemia cells, among which 5fdC is the most toxic to HL-60 cells, while THP-1 cells are most sensitive to 5hmdU.
[0050] (2) Mechanisms of the different effects of epigenetic modified nucleosides on the proliferation of acute myeloid leukemia cells
[0051] Figure 1 The results showed that 5fdC had significant differences in inhibition rates for two different acute myeloid leukemia cell lines after 144 hours of culture: the proliferation inhibition rate for HL60 was about 83%, while there was no significant inhibitory effect on THP-1.
[0052] ① Design a comparative experiment to detect the proliferation of cells under different treatments. β-ME was also added to the culture medium of 5fdC and HL-60, and compared with the group without addition. Figure 2 As shown in Figure A, the presence of β-ME in the culture medium did not weaken the inhibitory effect of 5fdC on the proliferation of HL-60 cells.
[0053] In addition, β-ME was withdrawn from the culture environment of 5fdC and THP-1, and the proliferation was compared with that of the group without β-ME withdrawal. Figure 2 As shown in B, even if β-ME was not present in the culture medium, the inhibitory effect of 5fdC on THP-1 proliferation was not enhanced, demonstrating that the presence of β-ME did not affect the toxicity of 5fdC.
[0054] ② In addition to oxidation reactions, bases in mammalian cells also undergo deamination reactions to generate corresponding deaminated products. The epitope-modified nucleosides 5hmdU, 5hmdC, and 5fdC cannot be phosphorylated by cytidine monophosphate kinase 1 (CMPK1), so they cannot be directly inserted into the genome without cytotoxicity. However, after being deaminated by intracellular CDA, they produce cytotoxic uridine derivatives 5hmdU and 5fdU. After 5hmdU and 5fdU are inserted into genomic DNA, they cause extensive DNA damage, thereby inducing cell cycle arrest and cell death.
[0055] Therefore, the present invention speculates that the difference in the expression of CDA in cells causes the difference in the degree of response of HL-60 and THP-1 acute myeloid leukemia cells to 5fdC. The present invention compares the expression of CDA in HL-60 and THP-1 cells by real-time fluorescence quantitative PCR (qPCR). The detection primers are:
[0056] Upstream primer (SEQ ID No. 1): CCCTACAGTCACTTTCCTG,
[0057] Downstream primer (SEQ ID No. 2): CGGGTAGCAGGCATTTTCTA.
[0058] The results are as follows Figure 2 As shown in Figure B, the expression level of CDA in HL-60 cells is much higher than that in THP-1 cells (about 7 times). This result indicates that the high sensitivity of HL-60 cells to 5fdC epitope-modified nucleosides is likely driven by the high expression of CDA in the cells.
[0059] ③ In order to further verify the relationship between 5fdC and intracellular CDA expression, the present invention uses the CDA inhibitor tetrahydrouridine (THU) to inhibit the activity of CDA highly expressed in HL-60 cells, and investigates the effect of 5fdC on the proliferation of HL-60 cells with inhibited CDA activity.
[0060] The results are as follows Figure 2 As shown in C, THU inhibited the activity of CDA and significantly weakened the inhibitory effect of 5fdC on the proliferation of HL-60 cells, indicating that the cytotoxic effect of 5fdC may depend on the highly expressed CDA in acute myeloid leukemia cells.
[0061] ④Construction of THP-1 cells with high expression of CDA (THP-1(CDAOE))
[0062] After designing and synthesizing the pLVX-EF1a-hCDA(NM_001785)-EGFP-IRES-Puro plasmid ( Figure 3A), double digestion with BamHI and EcoRI was performed and the plasmid was tested for correctness by agarose gel electrophoresis. The 1175 bp small fragment and 8790 bp large fragment displayed by the digestion product in the digestion lane indicated the correctness of the plasmid ( Figure 3 The sequencing results also further confirmed the correctness of the plasmid ( Figure 3 Next, the plasmid was transfected into HEK293T cells to amplify the lentivirus overexpressing CDA. The collected lentivirus was concentrated and titered, and then used to infect THP-1 cells. Within 96 hours after infection, some cells could be seen expressing green fluorescent protein ( Figure 3 D). Finally, 6 μg / mL of puro was added to screen the cells. The qPCR gel electrophoresis products were further tested to verify the expression of the overexpression plasmid in the cells. The results showed that the bands of the NC group and the wild type were lighter, and the bands of the CDA overexpression group were darker ( Figure 3 Middle E) shows that the THP-1 cell overexpressing CDA cell line was successfully constructed.
[0063] The relationship between the cytotoxicity of 5fdC and the expression level of CDA was verified by cell proliferation inhibition experiments. Figure 2 As shown in D, in THP-1 cells with high CDA expression (CDA OE), the inhibitory effect of 5fdC on cell proliferation was significantly enhanced.
[0064] In summary, intracellular CDA is the key factor in the toxicity of 5fdC, which lays the foundation for the application potential of 5fdC in the treatment of acute myeloid leukemia with high CDA expression.
[0065] (3) Mechanism of action of epitope-modified nucleosides on the inhibition of HL-60 and THP-1 cell proliferation
[0066] The present invention firstly detects the apoptosis of cells after continuous treatment with different epigenetic modified nucleosides by flow cytometry, and uses 5mdC without obvious cytotoxicity as a control. Figure 4 As shown in the figure, 5fdC can significantly induce apoptosis of HL-60 cells. However, in THP-1 cells, 5hmdU causes apoptosis of THP-1 cells. The data of apoptosis detection are highly consistent with the data of cell proliferation detection, indicating that epi-modified nucleosides inhibit cell proliferation by inducing apoptosis. It can be seen that epi-modified nucleosides inhibit cell proliferation by triggering cell apoptosis.
[0067] (4) Changes in γ-H2AX content after treatment with different epitope-modified nucleosides
[0068] When DNA in cells is damaged, the 139th serine residue of the histone variant H2AX will be rapidly phosphorylated at the damaged DNA site to form γ-H2AX. Therefore, the content of γ-H2AX protein can be used as an indicator of DNA damage.
[0069] The present invention detected the changes of γ-H2AX after being treated with different epigenetic modified nucleosides by Western Blot. Figure 5 As shown in Figure 2, after treatment with 5fdC, 5hmdC, and 5hmdU, the γ-H2AX protein content in HL-60 cells increased to varying degrees, with the 5fdC treatment group being the most obvious ( Figure 5 In contrast, in THP-1 cells, the γ-H2AX protein content in the 5hmdU-treated group was significantly increased compared with that in the DMSO group (P<0.01) ( Figure 5 C and D). The above results suggest that epigenetic modified nucleosides can cause DNA damage in leukemia cells, thereby inducing cell apoptosis.
[0070] (5) The extent of DNA damage caused by epigenetic modified nucleosides in acute myeloid leukemia cells
[0071] The present invention observed the DNA fragmentation of HL-60 and THP-1 cells after being treated with epitope-modified nucleosides by comet assay. Figure 5 As shown in Figure 2, compared with the other epigenetic modification nucleoside treatment groups, HL-60 cells treated with 5fdC and 5hmdC showed trailing and significantly longer comet tails ( Figure 5 In THP-1 cells, compared with the DMSO group, cells in the 5hmdU-treated group also showed tailing and obvious comet tails ( Figure 5 G and H), the comet tails of cells in the 5hmdC and 5fdC treatment groups also increased. The above results collectively indicate that epigenetic modified nucleosides can cause DNA breakage in acute myeloid leukemia cells, leading to cell apoptosis. The DNA damage of epigenetic modified nucleosides to leukemia cells depends on the expression level of CDA in cells, which lays the foundation for the targeted therapy of non-classical epigenetic modified nucleosides.
[0072] (6) Cell proliferation recovery after treatment with epigenetic modified nucleosides 5fdC and 5hmC
[0073] Severe DNA damage in cells can cause genome breakage, and the resulting inhibition of cell proliferation may be an irreversible process. Accordingly, the present invention uses non-cytotoxic 5mdC as a control to further investigate the recovery of cell proliferation after treatment with epigenetic modified nucleosides 5fdC and 5hmC. After HL-60 and THP-1 cells were incubated with 5fdC for 96 hours, 5fdC showed significant inhibition of the proliferation of both cells. At this point, the drug treatment was removed and cultured for 196 hours. It was found that the proliferation of the two cells did not recover after the drug was removed ( Figure 6 A and B), indicating that serious gene damage occurred in both cells after 5fdC treatment. The above results collectively indicate that the specific killing of acute myeloid leukemia cells by epigenetic modification nucleosides is through causing DNA breakage of cells, ultimately inducing cell apoptosis and exerting a proliferation inhibitory effect.
[0074] (7) Targeted toxicity of epigenetically modified nucleosides on acute myeloid leukemia cells with high CDA expression
[0075] The present invention selects normal kidney cells HEK293 as negative control cells to investigate the cytotoxicity of epitope-modified nucleosides. To this end, the present invention first investigates the apoptosis of HEK293 cells after co-incubation with epitope-modified nucleosides for 144 hours by flow cytometry. The results are as follows: Figure 7 As shown in Figures A and B, the effect of epi-modified nucleosides on the apoptosis of HEK293 cells is almost negligible, which means that 5fdC has no obvious toxicity to normal cells. Then, Western Blot and comet assays further verified that epi-modified nucleosides only cause slight damage to HEK293 cell DNA ( Figure 7 C and D). The above experimental results collectively indicate that epigenetically modified nucleosides have only slight toxic side effects on normal cells, but the toxic side effects are much smaller than those on tumor cells, suggesting that epigenetically modified nucleosides have specificity in killing acute myeloid leukemia cells with high CDA expression.
[0076] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.
Claims
1. Application of epigenetically modified nucleosides in the preparation of drugs for treating tumors, It is characterized in that The apparent modified nucleosides include at least one of the following: 5-aldehyde cytidine, 5-hydroxymethyl cytidine and 5-hydroxymethyl uridine.
2. The use according to claim 1, It is characterized in that The tumors include blood cancers.
3. The use according to claim 1, It is characterized in that The tumor treatment includes inhibiting the proliferation of cancer cells.
4. The use according to claim 3, It is characterized in that The cancer cells include acute myeloid leukemia cells.
5. The use according to claim 4, It is characterized in that The acute myeloid leukemia cells include HL-60 cells and / or THP-1 cells.
6. A tumor cell proliferation inhibitor, It is characterized in that comprising at least one of the following: 5-aldehyde cytidine, 5-hydroxymethyl cytidine and 5-hydroxymethyl uridine; Among them, 5-formylcytidine, 5-hydroxymethylcytidine, and 5-hydroxymethyluridine all inhibited the proliferation of HL-60 cells; 5-Hydroxymethyluridine has an inhibitory effect on the proliferation of THP-1 cells.
7. A targeted drug that inhibits acute myeloid leukemia cells with high CDA expression, It is characterized in that The active ingredient includes 5-formylcytidine.
8. The targeted drug according to claim 7, It is characterized in that This involves treating acute myeloid leukemia cells that highly express CDA with 5-acetylcytidine.
9. The targeted drug according to claim 8, It is characterized in that During the treatment, the concentration of 5-formylcytidine is not less than 10 μM and the treatment time is not less than 48 hours.
10. The targeted drug according to claim 8, It is characterized in that The acute myeloid leukemia cells with high CDA expression include HL-60 cells.
Citation Information
Patent Citations
Engineered immune cell therapy
CN117377756A
Deoxycytidine or uridine derivatives for treatment of cancer
CN118078850A
5-Tri:fluoromethyl-2'-desoxy-cytidine antitumour agents - releases tri:fluoro:thymidine slowly in situ and effective against tumours with high cytidine deaminase content
DE3007777A1
Oncolytic viruses and therapeutic molecules
US20190330655A1
Cited By
Nucleic acid aptamer-drug conjugate, preparation method thereof and application of nucleic acid aptamer-drug conjugate in preparation of anti-tumor drugs
CN121570603A
Aptamer-drug conjugate, preparation method thereof and application thereof in preparing anti-tumor drugs
CN121570603B
